Alembic Pharmaceuticals Limited (APLLTD) Share Price
NSE · Healthcare · Drug Manufacturers - Specialty & Generic · ISIN INE901L01018
Key metrics
- Market Cap
- ₹16,153 Cr
- P/E Ratio
- 23.31
- EPS
- 35.25
- Book Value
- 288.41
- P/B Ratio
- 2.83
- ROE
- 11.9%
- ROCE
- 11.32%
- Debt / Equity
- 0.25
- Net Margin
- 9.36%
- Revenue Growth
- 10.29%
- Profit Growth
- 15.66%
- Dividend Yield
- 1.47%
- 52W High
- ₹998.00
- 52W Low
- ₹635.80
- Market Cap Band
- mid cap
- Face Value
- 2
Ratios computed from the annual results period ending 2026-03-31.
About Alembic Pharmaceuticals Limited
Alembic Pharmaceuticals Limited, an integrated pharmaceutical company, develops, manufactures, markets, and sells pharmaceutical products in India and internationally. The company provides products in various therapeutic areas, such as cardiology, orthopaedics, anti-diabetic, ophthalmology, gynaecology, nephrology, gastrology, urology, dermatology, anti-infective, cold and cough, and animal health; generics formulations in oral solids, oncology oral solids and injectables, general injectables and ophthalmic products, dermatology, and oral suspension; and active pharmaceutical ingredients. It also exports its products. Alembic Pharmaceuticals Limited was founded in 1907 and is headquartered in Vadodara, India.
- Headquarters
- Vadodara, India
- Employees
- 17,244
- Promoter Holding
- 70.67%
The full Alembic Pharmaceuticals Limited analysis
Create a free account to open the complete APLLTD deep-dive — fourteen tabs of fundamental, technical, institutional and ownership data.
- 10-year financialsIncome statement, balance sheet and cash flow, year by year.
- Valuation & fair valueFair-value estimates, quality scores and a value grade.
- Charts & technicalsCandlestick charts, RSI, MACD, Supertrend and detected patterns.
- Shareholding historyPromoter, FII, DII and public holdings across every quarter.
- Ace investor holdingsWhich well-known investors hold it, and how their stake changed.
- Deals & insider tradesBulk and block deals, insider transactions and mutual-fund holdings.